BEX3 and diffuse large B-cell lymphoma: Significantly reduced GI50 values of BEX when it was co-administered with RA demonstrated improved potency and synergy of BEX and RA in DLBCL (Supplementary Material 2 and Supplementary Material Fig. S4).